Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated weight loss solutions company commercializing the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, announces that its Board of Directors has decided to explore potential financial and strategic alternatives intended to enhance stockholder value. The Company has engaged Canaccord Genuity LLC as its financial advisor. The overall uncertainty, the restriction on elective procedures and the specific directives issued by the Governor of California regarding Covid-19 has had an immediate impact on Obalon’s business.

Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 17) * BioNTech SE - ADR (NASDAQ: BNTX) * Regeneron Pharmaceuticals Inc (NASDAQ: REGN) ( Updated on its COVID-19 treatment development plan)Down In The Dumps (Biotech Stocks Hitting 52-week lows on March 17) * Abeona Therapeutics Inc (NASDAQ: ABEO) * AC Immune SA (NASDAQ: ACIU) * Acasti Pharma Inc (NASDAQ: ACST) * Accelerate Diagnostics Inc (NASDAQ: AXDX) * Acorda Therapeutics Inc (NASDAQ: ACOR) * Adamis Pharmaceuticals Corp (NASDAQ: ADM) * ADDEX THERAPEUT/ADR (NASDAQ: ADXN) * ADMA Biologics Inc (NASDAQ: ADMA) * Aerie Pharmaceuticals Inc (NASDAQ: AERI) * Agenus Inc (NASDAQ: AGEN) * Aimmune Therapeutics Inc (NASDAQ: AIMT) * Aldeyra Therapeutics Inc (NASDAQ: ALDX) * Alkermes Plc (NASDAQ: ALKS) * Allogene Therapeutics Inc (NASDAQ: ALLO) * Alpine Immune Sciences Inc (NASDAQ: ALPN) * AngioDynamics, Inc. (NASDAQ: ANGO) * Anika Therapeutics Inc (NASDAQ: ANIK) * Antares Pharma Inc (NASDAQ: ATRS) * Apellis Pharmaceuticals Inc (NASDAQ: APLS) * Applied Genetic Technologies Corp (NASDAQ: AGTC) * Aptinyx Inc (NASDAQ: APTX) * Aridis Pharmaceuticals Inc (NASDAQ: ARDS) * Artelo Biosciences Inc (NASDAQ: ARTL) * Assertio Therapeutics Inc (NASDAQ: ASRT) * Atara Biotherapeutics Inc (NASDAQ: ATRA) * Athenex Inc (NASDAQ: ATNX) * Avrobio Inc (NASDAQ: AVRO) * Axonics Modulation Technologies Inc (NASDAQ: AXNX * Bio-Path Holdings Inc (NASDAQ: BPTH) * Biocept Inc (NASDAQ: BIOC) * BioDelivery Sciences International, Inc. (NASDAQ: BDSI) * BIOFRONTERA AG/ADR (NASDAQ: BFRA) * Biohaven Pharmaceutical Holding Co Ltd (NYSE: BHVN) * BIOLASE Inc (NASDAQ: BIOL) * Biomerica, Inc. (NASDAQ: BMRA) * BioTelemetry Inc (NASDAQ: BEAT) * bluebird bio Inc (NASDAQ: BLUE) * BridgeBio Pharma Inc (NASDAQ: BBIO) * CareDx Inc (NASDAQ: CDNA) * Catabasis Pharmaceuticals Inc (NASDAQ: CATB) * Catalent Inc (NYSE: CTLT) * Catalyst Pharmaceuticals Inc (NASDAQ: CPRX) * Celcuity Inc (NASDAQ: CELC) * Cerus Corporation (NASDAQ: CERS) * Chiasma Inc (NASDAQ: CHMA) * Coherus Biosciences Inc (NASDAQ: CHRS) * Conatus Pharmaceuticals Inc (NASDAQ: CNAT) * Corbus Pharmaceuticals Holdings Inc (NASDAQ: CRBP) * Crinetics Pharmaceuticals Inc (NASDAQ: CRNX) * DBV TECHNOLOGIE/S ADR (NASDAQ: DBVT) * Dynavax Technologies Corporation (NASDAQ: DVAX) * Edwards Lifesciences Corp (NYSE: EW) * Enanta Pharmaceuticals Inc (NASDAQ: ENTA) * Enzo Biochem, Inc. (NYSE: ENZ) * Erytech Pharma SA (NASDAQ: ERYP) * Evogene Ltd (NASDAQ: EVGN) * Evolus Inc (NASDAQ: EOLS) * EXACT Sciences Corporation (NASDAQ: EXAS) * Exelixis, Inc. (NASDAQ: EXEL) * Flexion Therapeutics Inc (NASDAQ: FLXN * G1 Therapeutics Inc (NASDAQ: GTHX) * Galectin Therapeutics Inc. Common Stock (NASDAQ: GALT) * Galera Therapeutics Inc (NASDAQ: GRTX) * Glaukos Corp (NYSE: GKOS) * Gossamer Bio Inc (NASDAQ: GOSS) * Guardant Health Inc (NASDAQ: GH) * GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH) * Haemonetics Corporation (NYSE: HAE) * Halozyme Therapeutics, Inc. (NASDAQ: HALO) * Hologic, Inc. (NASDAQ: HOLX) * Hoth Therapeutics Inc (NASDAQ: HOTH) * Ideaya Biosciences Inc (NASDAQ: IDYA) * Immunic Inc (NASDAQ: IMUX) * IMMURON LTD/S ADR (NASDAQ: IMRN) * Innoviva Inc (NASDAQ: INVA) * Insmed Incorporated (NASDAQ: INSM) * Inspire Medical Systems Inc (NYSE: INSP) * Intec Pharma Ltd (NASDAQ: NTEC) * Intercept Pharmaceuticals Inc (NASDAQ: ICPT) * Intuitive Surgical, Inc. (NASDAQ: ISRG) * Invivo Therapeutics Holdings Corp (NASDAQ: NVIV) * Jazz Pharmaceuticals PLC (NASDAQ: JAZZ) * Kindred Biosciences Inc (NASDAQ: KIN) * Kura Oncology Inc (NASDAQ: KURA) * Inspire Medical Systems Inc (NYSE: INSP) * Laboratory Corp. of America Holdings (NYSE: LH) * Lantheus Holdings Inc (NASDAQ: LNTH) * Ligand Pharmaceuticals Inc. (NASDAQ: LGND) * Madrigal Pharmaceuticals Inc (NASDAQ: MDGL) * Medigus Ltd. (NASDAQ: MDGS) * MeiraGTx Holdings PLC (NASDAQ: MGTX) * Merrimack Pharmaceuticals Inc (NASDAQ: MACK) * Mesoblast limited (NASDAQ: MESO) * Midatech Pharma PLC-ADR (NASDAQ: MTP) * Milestone Pharmaceuticals Inc (NASDAQ: MIST) * Miragen Therapeutics Inc (NASDAQ: MGEN) * Monopar Therapeutics Inc (NASDAQ: MNPR) * Morphic Holding Inc (NASDAQ: MORF) * Myriad Genetics, Inc. (NASDAQ: MYGN) * Natus Medical Inc (NASDAQ: NTUS) * Neovasc Inc (NASDAQ: NVCN) * Neurometrix Inc (NASDAQ: NURO) * Neuronetics Inc (NASDAQ: STIM) * NuVasive, Inc. (NASDAQ: NUVA) * OncoSec Medical Inc (NASDAQ: ONCS) * Oncternal Therapeutics Inc (NASDAQ: ONCT) * Orchard Therapeutics PLC - ADR (NASDAQ: ORTX) * Organovo Holdings Inc (NASDAQ: ONVO) * Orthofix Medical Inc (NASDAQ: OFIX) * Pacira Biosciences Inc (NASDAQ: PCRX) * PLx Pharma Inc (NASDAQ: PLXP) * Portola Pharmaceuticals Inc (NASDAQ: PTLA) * PRA Health Sciences Inc (NASDAQ: PRAH) * Precigen Inc (NASDAQ: PGEN) * Precipio Inc (NASDAQ: PRPO) * Precision BioSciences Inc (NASDAQ: DTIL) * Predictive Oncology Inc (NASDAQ: POAI) * Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX) * PTC Therapeutics, Inc. (NASDAQ: PTCT) * Puma Biotechnology Inc (NASDAQ: PBYI) * Quest Diagnostics Inc (NYSE: DGX) * Retrophin Inc (NASDAQ: RTRX) * Revolution Medicines Inc (NASDAQ: RVMD) * Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) * Rocket Pharmaceuticals Inc (NASDAQ: RCKT) * Rubius Therapeutics Inc (NASDAQ: RUBY) * SAGE Therapeutics Inc (NASDAQ: SAGE) * Sesen Bio Inc (NASDAQ: SESN) * Shockwave Medical Inc (NASDAQ: SWAV) * SI-Bone Inc (NASDAQ: SIBN) * Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) * Supernus Pharmaceuticals Inc (NASDAQ: SUPN) * Syros Pharmaceuticals Inc (NASDAQ: SYRS) * T2 Biosystems Inc (NASDAQ: TTOO) * Tandem Diabetes Care Inc (NASDAQ: TNDM) * Tcr2 Therapeutics Inc (NASDAQ: TCRR) * TELA Bio Inc (NASDAQ: TELA) * Tetraphase Pharmaceuticals Inc (NASDAQ: TTPH) * TherapeuticsMD Inc (NASDAQ: TXMD) * Titan Medical Inc. (NASDAQ: TMDI) * TrovaGene Inc (NASDAQ: TROV) * Twist Bioscience Corp (NASDAQ: TWST) * Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) * Urogen Pharma Ltd (NASDAQ: URGN) * Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) * Varian Medical Systems, Inc. (NYSE: VAR) * Vericel Corp (NASDAQ: VCEL) * Viking Therapeutics Inc (NASDAQ: VKTX) * X4 Pharmaceuticals Inc (NASDAQ: XFOR) * X T L Biopharmaceuticals Ltd (NASDAQ: XTLB) * Xencor Inc (NASDAQ: XNCR) * ZIOPHARM Oncology Inc. (NASDAQ: ZIOP) * Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE)See Also: 8 Biotechs With Coronavirus Vaccines In DevelopmentStocks In Focus Vaxart, Emergent Join Hands For Oral COVID-19 Vaccine, Clinical Trials to Begin In 2020 Vaxart Inc (NASDAQ: VXRT) said it has entered into an agreement with Emergent Biosolutions Inc (NYSE: EBS), which will allow Emergent to deploy its molecule-to-market contract development and manufacturing services to develop and manufacture the former's oral vaccine candidate for COVID-19."We believe an oral vaccine administered using a room temperature-stable tablet may offer enormous logistical advantages in the roll-out of a large vaccination campaign, and Emergent is a great partner to help in this endeavor," SAID Wouter Latoud, CEO of Vaxart.Vaxart expects Emergent to produce bulk cGMP vaccine to allow it to initiate Phase 1 study in the second hand of 2020.In pre-market trading Wednesday, Vaxart shares were rallying 23.32% to $2.38.IMV Jumps Into The Fray For COVID-19 Vaccine Imv Inc (NASDAQ: IMV) said it's advancing the clinical development of a DPX-based vaccine candidate against COVID-19. It intends to develop its vaccine candidate DPX-COVID-19 in collaboration with lead investigators for the phase 1 clinical studyAbbVie, Allergan Agree To Divest Certain Assets To Consummate Proposed Merger AbbVie Inc (NYSE: ABBV) and Allergan plc (NYSE: AGN) said they have entered into a consent decree agreement with the FTC staff regarding the former acquiring the latter. Under the agreement, the companies agreed to divest brazikumab, an investigational autoimmune disorder drug, to AstraZeneca plc (NYSE: AZN), and Zenpep, a treatment for exocrine pancreatic insufficiency due to cystic fibrosis and other conditions, as well as Viokace, another pancreatic enzyme preparation, both to NESTLE S A/S ADR (OTC: NSRGY).View more earnings on IBBThe companies expect the deal to close in May 2020, compared to the initial deadline of early 2020.In after-hours trading, shares of AbbVie slipped 1.47% to $71.95, while Allergan shares rose 1.84% to $175.Addex To Delay Parkinson's Disease Drug Registrational Study, Release of Q4 Results Addex has postponed the start of the registrational efficacy and safety study of dipraglurant to treat levodopa induced dyskinesia in patients with Parkinson's disease due to the COVID-19 pandemic. The company also announced delaying the release of its fourth quarter results till April 8.Biomerica Begins International Shipments of COVID-19 Rapid Test Biomerica said it has commenced shipping initial samples of its COVID-19 IgG/IgM Rapid Test - a finger prick test with results in 10 minutes - to countries outside of the U.S."Biomerica is positioned to begin filling large international orders of this disposable one-use tests within weeks, assuming international product shipping channels remain open and active," the company said. The company has also begun the application process with the FDA for Emergency Use Authorization for its COVID-19 test.Qiagen To Ramp Up Production If COVID-19 Testing Reagents By 7 Times Qiagen NV Qiagen NV (NYSE: QGEN) said it plans to dramatically ramp global production capacity of RNA extraction kits used as part of workflows around the world to detect nucleic acid from SARS-CoV-2, the virus that causes COVID-19.From its historical capacity of manufacturing RNA nucleic acid extraction reagents for 1.5 million patient tests on a monthly basis, Qiagen now plans to ramp production of reagents to support more than 6.5 million patient tests a month by the end of April 2020 and over 10 million patient tests a month by the end of June.Obalon To Halt Sale of Weight Loss System In California Due To COVID-19 Obalon Therapeutics Inc (NASDAQ: OBLN), which markets the first FDA-approved swallowable gas-filled intragastric balloon system for treating obesity, said it has temporarily suspended sale of the system at its existing retail treatment centers in San Diego and Orange County, California in the wake of the COVID-19 threat.Earnings Diffusion Pharmaceuticals Inc (NASDAQ: DFFN) reported a narrowing of its fourth-quarter loss from $8.21 in 2018 to $1.76 in 2019. Cash and cash equivalents stood at $14.2 million as of Dec. 31, 2019, compared with $8 million at Dec. 31, 2018.The stock jumped 22.46% to 35 cents in after-hours trading.On The Radar Clinical Readouts Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) is due to present at the Annual Congress on Pulmonology & Respiratory Medicine, already-released Phase 2 data for Poziotinib in non-small cell lung cancer with exon 20 insertion mutation in EGFR or HER2.Earnings Brickell Biotech Inc (NASDAQ: BBI) (after the close) Cumberland Pharmaceuticals, Inc. (NASDAQ: CPIX) (after the close) Capricor Therapeutics Inc (NASDAQ: CAPR) (after the close) Turning Point Therapeutics Inc (NASDAQ: TPTX) (after the close) Osmotica Pharmaceuticals PLC (NASDAQ: OSMT) (after the close)See more from Benzinga * 10 Small-To-Mid-Cap Biotech Ideas For When The Coronavirus Fades * The Daily Biotech Pulse: Setback For DBV In Peanut Allergy Patch Review, Roche Starts Coronavirus Test Shipment, Regeneron Aims For 'Cocktail' COVID-19 Treatment(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

OBALON THERPTCS (OBLN) delivered earnings and revenue surprises of 82.57% and -84.86%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

The big shareholder groups in Obalon Therapeutics, Inc. (NASDAQ:OBLN) have power over the company. Generally speaking...

Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated weight loss solutions company commercializing the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, announces that William Plovanic, the Company’s President and CEO has announced his resignation in order to accept another position. To assist the Company in the transition, Mr. Plovanic has agreed to remain as President and CEO through completion and filing of Obalon’s Form 10-Q for the quarter ended March 31, 2020 (the “Quarterly Report”).

SAN DIEGO, Feb. 27, 2020 -- Obalon Therapeutics, Inc. (NASDAQ: OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable,.

Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated weight loss solutions company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, announces that it has entered into a one-year agreement with Al Danah Medical Company (“Al Danah”) for distribution of the Obalon Navigation Balloon System in Qatar. Obalon has terminated its agreement with Bader Sultan and Bros. Company for distribution of its prior-generation balloons, which was set to expire on December 31, 2019.

Q4 2019 Obalon Therapeutics Inc Earnings Call

SAN DIEGO, Feb. 13, 2020 -- Obalon Therapeutics, Inc. (NASDAQ: OBLN), a weight loss solutions company with the first and only FDA-approved swallowable, gas-filled intragastric.

Obalon Therapeutics, Inc. (“Obalon” or the “Company”) (NASDAQ:OBLN), a vertically integrated weight loss solutions company commercializing the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, announces changes related to the impacts of the Covid-19 crisis and current business environment on its business, organization and strategic options. As previously announced, the overall uncertainty, the restriction on elective procedures and the specific directives issued by the Governor of California as a result of Covid-19 have had a significant impact on Obalon’s business. In March, the Company halted sales to new patients in its company-branded retail treatment centers and expansion plans for additional retail centers, which was particularly disappointing as it had generated an average of approximately 30 new patient sales per month at its San Diego center for the three months preceding the Covid-19 crisis.

We often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are...

Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated weight loss solutions company commercializing the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, announces that it has entered into a new common stock purchase agreement and registration rights agreement (together, the “Agreements”) with Lincoln Park Capital Fund, LLC (“LPC”), a Chicago-based institutional investor, for up to $15 million. The new Agreements replace existing agreements between the Company and LPC. Under the terms of the Agreements and following the filing and effectiveness of a registration statement, Obalon will have the right at its sole discretion to sell to LPC up to $15 million worth of shares over a 36-month period, subject to various limitations including those under the NASDAQ listing rules.

Obalon Therapeutics, Inc. (OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity provided further clarification that it’s gas-filled balloon is not the subject of the April 27, 2020 letter issued by the FDA to health care providers warning of serious potential risks, including deaths, associated with the use of liquid-filled intragastric balloons. The Obalon swallowable, gas-filled balloon system utilizes a very different design and technology than the liquid-filled balloons cited now in four FDA letters to health care providers.

Q3 2019 Obalon Therapeutics Inc Earnings Call

Spindletop Capital Management, a healthcare-focused growth equity firm, is pleased to announce the promotion of Kelly Huang, Ph.D. as a Managing Director of Spindletop Capital. The promotion was in recognition of Dr. Huang's role in identifying successful growth equity investments and working closely with portfolio companies' management teams to accelerate revenue and profit growth. Dr. Huang first joined Spindletop Capital in 2014 as an advisor and operating partner.

Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated weight loss solutions company commercializing the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, announces that it has temporarily suspended sales of its novel weight loss treatment to new patients at its existing retail treatment centers in San Diego and Orange County, California as a precaution against the spread of the coronavirus (COVID-19). The retail treatment centers will continue to fully treat and care for patients already in treatment with the Obalon Balloon System, and non-essential personnel will work remotely. “The safety, health and well-being of our patients, employees and providers remain our highest priority, therefore we are taking these steps to mitigate the impact of COVID-19 at Obalon retail facilities,” said Bill Plovanic, President and Chief Executive Officer of Obalon.

Alternatives may include equity or debt financing, sale of the company, business combination, merger or reverse merger with another party, the company said. The COVID-19 crisis has significantly impacted Obalon’s stock price and its ability to access additional capital, the company added.

Is (OBLN) Outperforming Other Medical Stocks This Year?

SAN DIEGO, Nov. 14, 2019 -- Obalon Therapeutics, Inc. (NASDAQ: OBLN), a weight loss solutions company focused on commercializing the Obalon Balloon System, the first and.

Obalon Therapeutics, Inc. (NASDAQ: OBLN), a vertically integrated weight loss solutions company commercializing the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, announces that it has opened its second Company-managed retail treatment center. “We are excited to have opened the second Company-managed Obalon Center for Weight Loss™, further developing our strategy to build a standardized, repeatable business using a Company-owned or managed retail treatment center model,” said Bill Plovanic, President and Chief Executive Officer of Obalon.